Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 50
Appendix B
Speaker Biographies
PANEL 1: PARTICIPANT CENTERED CLINICAL
RESEARCH
MODERATOR-MYRL WEINBERG
MARSHALL H. CHIN, M.D., M.P.H., is Associate Pro-
fessor of Medicine, Associate Director of the Robert Wood
Johnson Clinical Scholars Program, and Director of the
NIDDK Diabetes Research and Training Center Prevention
and Control Core at the University of Chicago. He is a gen-
eral internist whose research focuses on improving the care
and outcomes of vulnerable patients with chronic disease in
community health centers. Dr. Chin' s current work tests mul-
tifactorial, community-based interventions including rapid
quality improvement, chronic disease management, provider
training in behavioral change, and patient empowerment. He
received the 2001 National Association of Community
Health Centers Innovative Research in Primary Care Award.
Dr. Chin received his M.D. from the University of Califor-
nia at San Francisco, and completed residency and fellow-
ship training in general internal medicine at Brigham and
Women's Hospital, Harvard Medical School.
LAWRENCE W. GREEN, Dr.P.H., is the first director of
the CDC Office of Science and Extramural Research and
Associate Director for Prevention Research and Academic
Partnerships in CDC's Public Health Practice Program Of-
fice. He served as Acting Director of CDC's Of lice on Smok-
ing and Health and director of the WHO Collaborating Cen-
ter on Tobacco and Health, with responsibility for the
development and coordination of CDC' s global tobacco con-
trol strategy in collaboration with the World Health Organi-
zation. Prior to joining the CDC, he served as Director of the
Institute of Health Promotion Research and Professor and
Head of the Division of Preventive Medicine and Health Pro-
motion, Department of Health Care and Epidemiology, at
the University of British Columbia.
50
ZELDA TETENBAUM, a science and health educator, is a
member of the NIH Director's Council of Public Represen-
tatives. Her work as a patient advocate began in 1996 when
her adult son was diagnosed with a brain tumor, glioblas-
toma multiforme. During her search for information about
her son's illness, Ms. Tetenbaum has been involved with the
American Brain Tumor Association and the Central Brain
Tumor Registry of the United States, and the North Ameri-
can Brain Tumor Coalition (NABTC), a network of 13 chari-
table organizations dedicated to eradicating brain tumors.
Currently, Ms. Tetenbaum serves on NABTC's Board of
Directors and as Chairperson of its Advocacy Committee. In
addition to her volunteer and advocacy work, Ms.
Tetenbaum has devoted much of her professional life to edu-
cation. She was a science teacher at a junior high school in
Illinois for 21 years. When she retired in 1990, Ms.
Tetenbaum worked on a National Science Foundation
Teacher Enhancement Program at the U.S. Department of
Energy's Argonne National Laboratory. Currently, Ms.
Tetenbaum consults for her local school district in Illinois.
JEROME W. YATES, M.D., M.P.H., is the National Vice
President for Research at the America Cancer Society. Prior
to joining ACS, Dr. Yates was the Senior Vice President for
Population Sciences at Roswell Park Cancer Institute. At
Roswell Park Cancer Institute, he was involved in efforts to
improve the prevention program and in the redefining of
clinical research priorities across the institute. Previously,
Dr. Yates served as the Associate Director for Centers and
Community Oncology at the National Cancer Institute,
where he was part of the group responsible for the genera-
tion and subsequent evaluation of the Community Clinical
Oncology Program (CCOP). He was also a participant in the
NCI-funded research on pain in connection with the CCOP.
Dr. Yates received his M.D. from the University of Illinois
in Chicago and an M.P.H. from Harvard.
OCR for page 51
APPENDIX B
PANEL 2: MODEL COLLABORATIONS AMONG
COMMUNITY/ DISEASE ADVOCATES,
RESEARCHERS, AND SPONSORS
MODERA TOR - LARRY GREEN
JENNIFER BRYSON is the Director of Corporate Affairs
at Genentech, Inc., a leading biotechnology company head-
quartered in South San Francisco, CA. Ms. Bryson brings
extensive experience in advocacy relations and longstanding
relationships with the cancer community and other patient
advocacy groups. She has been instrumental in the growth of
innovative collaborations between Genentech and patient
communities. During the development of Herceptin, a novel
breast cancer therapy, Ms. Bryson facilitated a unique and
lasting partnership between the company and breast cancer
advocates, which helped quickly enroll clinical trials and
make the treatment widely available to patients. Before join-
ing Genentech in 1999, Ms. Bryson held positions at
Ketchum Public Relations and Bass and Howes, Inc in
Washington, DC. Prior to her work at these firms, Ms.
Bryson worked on several statewide campaigns for women
candidates. She holds a bachelor's degree from Mount
Holyoke College.
KENNETH A. BERTRAM, M.D., Ph.D., F.A.C.P., Colo-
nel, U.S. Army Medical Corps, is the Director of the Con-
gressionally Directed Medical Research Programs
(CDMRP) at Fort Detrick, Maryland. He directs all facets of
the DOD breast cancer, prostate cancer, ovarian cancer, neu-
rofibromatosis, and other peer reviewed medical research
programs, totaling $2.2 billion for the USAMRMC. COL
Bertram holds an Assistant Professor appointment at the
Uniformed Services University of the Health Sciences. He
obtained both his Ph.D. and his M.D. from the University of
Minnesota. He then moved to Madigan Army Medical Cen-
ter, where he completed his Internal Medicine residency and
Hematology/Oncology Fellowship and later served as Chief,
Hematology/Oncology Service. COL Bertram has conducted
translational research in breast cancer and participated as a
site Principal Investigator in the Southwest Oncology Group
clinical trials.
LESLIE FORD, M.D., is Associate Director for Clinical
Research and Acting Deputy Director of the Division of
Cancer Prevention at the National Cancer Institute. She is
responsible for the overall direction, conceptualization, plan-
ning, and coordination of cancer prevention clinical trials at
NCI. She has over 20 years experience in bringing cancer
clinical trials into community medical practices. As Chief of
the Community Oncology and Rehabilitation Program, she
expanded the Community Clinical Oncology Program
(CCOP), through which more than 10,000 men and women
are accrued each year to NCI-sponsored treatment and pre-
51
vention clinical trials. She received her B.S. and M.D. from
SUNY Buffalo.
KEN OLDEN, Ph.D., was named as the third director of the
National Institute of Environmental Health Sciences
(NIEHS) and the second director of the National Toxicology
Program (NTP) in June 1991. Dr. Olden is a cell biologist
and biochemist by training, and has been active in cancer
research for almost three decades. He was director of the
Howard University Cancer Center and professor and chair-
man of the Department of Oncology at Howard University
Medical School (1985-1991), Washington, D.C., before join-
ing NIEHS. He joined Howard in 1979 as Associate Direc-
tor for Research after a stint at the National Institutes of
Health, first as a senior staff fellow, second as an expert,
then a research biologist in the Division of Cancer Biolo~v
and Diagnosis, National Cancer Institute.
~7~
FRAN M. VISCO, J.D., is the first President of the Na-
tional Breast Cancer Coalition (NBCC) and a member of its
Board of Directors. Formed in May 1991, NBCC is a
grassroots advocacy organization of more than 600 member
organizations and 70,000 individual members. Ms. Visco is
an honors graduate of St. Joseph's University and of
Villanova Law School where she was an editor of The
Villanova Law Review and a chair of the Women's Law
Caucus. In 1993, President Clinton appointed Ms. Visco to
the President's Cancer Panel and she was re-appointed for a
second term in 1996. Ms. Visco, who was elected to chair
the Integration Panel of the Department of Defense Peer-
Reviewed Breast Cancer Research Program, is the first con-
sumer to chair this panel. Ms. Visco co-chaired the National
Action Plan on Breast Cancer and serves on the National
Cancer Policy Board. Ms. Visco is a breast cancer survivor.
PANEL 3: INCREASING THE ROLE OF THE PUBLIC IN
RESEARCH OVERSIGHT
MODERATOR- QUETA BOND
ANGELA BOWEN, M.D., established the Western Institu-
tional Review Board (WIRB) in 1968 and has been the presi-
dent since 1991. She is a graduate of Mississippi State Uni-
versity and completed her postgraduate education in
research, medicine and endocrinology at the University of
Washington. Dr. Bowen has been active in clinical research,
as well as a consulting endocrinologist for over thirty years.
Her research interests have included tuberculosis, diabetes,
circadian rhythms and effects of hormone replacement
therapy. She is an accomplished speaker and a respected
author. Dr. Bowen participated in the working group to dis-
cuss revisions to the Declaration of Helsinki and in the de-
velopment of the Ethics Committee guidelines for develop-
ing countries. She is active in human subject protection.
OCR for page 52
NANCY DU:BLER, L.~.~., is the Director of He Division
of :Bioethic$, :Dep~ment Q! FipidemtQ}ogy and Social Medi-
c~ne at MonteOore Medical Center and P[Q~SSOr 0[ Epide-
miology and Social Medic~rte am the Albert :~nstein College
of Medicine. She received her B.A. from Bam~ College
and her LL.B~ Tom the Harvard Law School. Ms. Dubler
directs the Bioethics Consultation Service at Monte£iore
Medical Center (hounded In Ig78) as a support for analysis
of difficult clinical cases presenting ethical issues in the
health ewe setting. She lectures extensively and is the author
of numerous Stales and books. She Is Co-Director of the
Certificate Program in Bioethics Ed the Medical Hum~i-
t~es' conducted jointly by Montefiore Medical Cente~lAlbe~
Einstein College Of Medicine with The Hanford Institute Q!
Geriatric Nursing a! NOW YQ~ University.
DACTYL UNDERMAN, M.O., is the C=l W. Walter Dis-
tinguished Professor of Medicine and Medical Education at
Harvard Medical School In 130~0n, Massachusetts. He pre-
v~usly served on the faculty of lI~rard Medical School
groin 1960 to 1972, and was simultaneously on He stab of
He Massachusetts Gertem} Hospital. From 1972-77 he was
Ch~an of the Department of Medicine at Seward Medic
cal School. He then reWmed to Awed Medical School. Dr.
Federmm has served as Ch~= of the Amencan :Bo~d v!
:~ Medicine' Cha~ of the Federated Council for
In~al Medicine, and Resident of the Amenean College Q!
Phys~c~s. He ~s a member of the Insulate of Medicine. He
has received numerous awards Ruing the AAMC,s
Abraham FIe~ner Award for fished Service to Medi-
c~ Education In 200 ~ ~ Dr. Federm~ Waived his M.~. Mom
Awry Medical School. His clinical trmmog at Massachu-
setups ~~ Hospital was [Q1Iv~ed by rese=ch Awing
the Na0~ Institutes of Health He holds ~ D.Sc.7 honons
CAUSE, [(Qua M(. Sims SChOQ! Q! Medicine.
GREG KOSM, Mad.' Is the first Elton of the new ~~-
crat (;}~0ce far HuTn~ Research Protections (CAMP,) within
He Office of the Secretory of the Department of locale =d
Bump Sewices. He also chmrs the Humar~ Subjects Re-
se~ch Subcommittee (HS:RS) of the Nations Science and
Technology Council's Committee on Science. for to jo~-
ing OHRP? Dr. Koski spent more than thirty years at
Ha—~d, dunng which he p~tic~ed ~ ember facet of aca-
=e I~ =d human research. Under his leadership, the
Once ~r Bump Rese=ch Pro~cUons is moving from
reactive comph=~-~used system of oversight Ad sanc-
dons {Q ~ Dative system focused on p~vendon of he to
subjects~a system In which performance excellence is
achieve Rough education, support md quality im~?rove-
menl;. In colia6oradon with the Food Ad D=g Ad~mstra-
bon, the National It~St~S of Realm and Q(her ~~ agen-
cies? his office is working to indents new op~-~mt~es to
make on system [OF ~tecUon of bump suffers more cfO-
cient and mow effective.
ENGAGING THE PUBLIC IN THE CLINICAL i ~T~PR~E
MA~Q~ A. SPEARS, Ph.D., ~s the F~ecubve :~:rector
of the Association for the Accr-ed~tat~n of Lunar Research
Protection Programs (AAH~PPy, which employs a ~Q100-
tary, peer-~nven, educational model of accreditation. She
served at the National Bioethics Advisory Commission from
1999-2001, both as project Erector ~r a repot on He re-
search oversight system arid as Acting Executive Director.
Or. Speers was Deity Associate Aced ~r Science ~ the
Centers for Disease Compel afar Prevention (BLOC) Mom
1995-2000. She held ~ variety of positions ad CDC from
1988-1995: Director Q:{ the Division A TIC Disease
Control and Community Inteweintion, Chief of the Aging
Ad Statistics Branch? Ad smff epide~Iog~st. Pnor to join-
lug CDC, she was ~ faculty member at the University of
Texas Mental Branch =d the Adversity of Connecticut.
PANEL 4. STEPS TDi IMPROVE THE TRANSLATION
AND DISSEMINATION OF THE RESULTS OF CLINICAL
RESEARCH
MODERATOR - NANCY Sly
STEP~NT ~~:Z' M.~., Phyla., is Director Q! the Nations
Institute of Arthritis and Musculo$:1~elet~ and Son Diseases
at the Nylons ~sUtutes of Health and ~SQ se - ~s as calm of
the Demonology :Brmch of the National Cancer Institute.
:He received As undergraduate de~e fmm the UT~vers~ty of
May his MD from ~~ar~e Medico School, =d ~ Ph.~.
n immunology Cow the University of Condors. He has pre-
v~ously served ~ the Marion B. Suizberger ~o~ssor of
Dermatology ~ the Uniformed Services TJ~vers~ty of the
Heath Sciences. Dr. Katz is -the P=s~dent of bmb the Int~-
nabonal League of Dermatotog~£~ Societies arid the Inter-
nationa1 Co~ee of Dermatology. As a It
Immunologist, he has contributed to our basic and climes
knowledge about fin Ad skin diseases. He is ~ enemas of
the IBM.
JOHN W. WALSH was diagnosed with Alpha-l Ant~-
ryps~n Decency (Alpha-~) ~n 1989. fIe has ded;ica~d his
hoe? s work to promoting beseech and Onding a cure for the
disorder. In 1995 he estabUsh~ the Alpha-1 Foundation'
not-for-~:?rofit corporation dedicated to providing the leader-
s~p and resources to increase research, improve health, P[Q-
mom worldwide detection, Ad Ond ~ cure for Alpha-~. {n
Addison? he is co- - nder of Al~^et' a r~-~-proOt ~s-
e~e management comply s~eializ~g exclusively on Al-
pha-~' whew he serves ~ £hai~an =d Pasadena. Wash
se - es as ~ active member of vamps voluntary health
agency committees and goYemment~ advisory committees.
He has been Deed by He Sect of Heath Ad
Camaro Services to serve ~ second term on the Advisory
Co~hee on Blood Safety Ad Av~l~itity. He serves on
the Ardency Tic Society Public Advisory RoundRable,
OCR for page 53
APPENDIX B
the National Heart Lung and Blood Institute Public Informa-
tion Council, is on the Board of Directors of Primary Im-
mune Services, Inc., and is co-founder of the Plasma Users
Coalition.
BARRY W. WOLCOTT, M.D., serves as Senior Vice
President, Senior Medical Editor, Portal Services at WebMD
Corporation, employing his experience developing and inte-
grating patient-focused decision support systems. In January
2000, he joined CareInsite (which merged with WebMD in
September 2000~. Prior to joining WebMD, he was Chief
53
Medical Officer at Access Health. Dr. Wolcott served as as-
sociate professor and the first chairman of the Department of
Operational and Emergency Medicine at the F. Edward
Hebert School of Medicine in Washington, DC from 1982 to
1993. Today, he continues his academic appointment at the
F. Edward Hebert School of Medicine and has clinical privi-
leges at the Naval National Medical Center in Bethesda,
Maryland. Dr. Wolcott graduated from Johns Hopkins Uni-
versity School of Medicine in 1970 and completed his Inter-
nal Medicine residency at Walter Reed Army Medical Cen-
ter in Washington, D.C.
Representative terms from entire chapter:
cancer institute
